Objective: Several studies have evaluated the efficacy of continuous infusion of dexmedetomidine for procedural sedation of pediatric patients. There are few published reports of single dose dexmedetomidine for pediatric procedural sedation. We want to report on three pediatric patients who received single dose dexmedetomidine for procedural sedation.
INTRODUCTION
Dexmedetomidine is a relatively new, α 2 -adrenergic receptor agonist with both sedative and analgesic properties. 1 It is classified as a sedative by the FDA and approved for sedation of adults in intensive care unit setting for up to 24 hours. 2 Several studies have evaluated the efficacy of dexmedetomidine as an agent for procedural sedation in the pediatric patient population. 3 4 5 6 In these studies, sedation was achieved by giving dexmedetomidine in an induction dose followed by a continuous infusion. A single intravenous dose of 0.5 mcg/kg has been used to decrease postoperative agitation and post anesthesia shivering. 4 A recent study suggested the efficacy of bolus dosing of dexmedetomidine, followed by IV infusion, in sedating children for CT scans. 7 There are no reports on the efficacy of single dose dexmedetomidine for procedural sedation.
METHODS
Hospital records of patients undergoing procedural sedation with dexmedetomidine were obtained. Patients were identified from a log kept of all procedural sedations performed by the author. The following demographic data was obtained: age, weight, gender, and underlying medical condition. Information pertaining to dexmedetomidine included indication for administration, procedure performed, bolus dose given, and adverse effects that could be attributed to the medication. Vital signs were monitored per hospital sedation protocol, including blood pressure, heart rate, respiratory rate, and pulse oximetry, in five-minute intervals.
RESULTS
The demographic data, indication for use, and dose administered is presented in Table 1 . The following are brief descriptions of the individual cases.
Patient 1 is a 6 year old male who presented with fever and progressive pain in hip area and difficulty ambulating. MRI of the pelvis and femur was obtained to assess for septic hip, osteomyelitis and/or abscess. Dexmedetomidine 20 mcg IV was given over 10 minutes. 
DISCUSSION
Procedural sedation in children is a challenging endeavor. Several sedatives are used on a routine basis for different procedures, but none provide optimal safety profile, efficacy, and reliability.
Dexmedetomidine appears to be well tolerated by patients undergoing both painful and painless procedures. The hemodynamic changes related to blood pressure did not result in any intervention, difficulty during the sedation or during the recovery phase. Dexmedetomidine has been used effectively for sedation of pediatric patients, but always as either an infusion, or a loading dose followed by an infusion. The most common dosing parameter is a loading dose of 0.5-2 mcg/kg IV over 10-15 minutes, followed by an infusion of 0.25-1 mcg/kg/hr.
In this study, patients were given a higher loading dose, between 1-3 mcg/kg over 10-15 minutes. The patients tolerated the bolus well, and there was no need for additional bolus doses or maintenance infusions. The heart rate and blood pressure remained stable. Although an expected drop in blood pressure was recorded during the first 20 minutes after the initial bolus dose, none of the changes required intervention.
CONCLUSION
Dexmedetomidine is an effective agent for procedural sedation. It is usually dosed as either an infusion or a induction dose followed by an infusion. We report on the use of single dose dexmedetomidine for procedural sedations in children. A single 1-3 mcg/kg IV bolus dose over 10-15 minutes appears to provide adequate sedation for the performance of both painful and painless procedures in children. Further studies are needed to determine the safety and efficacy of this dosing regimen.
